Vigilant Biosciences Announces the Launch of the OncAlert Labs OraMark™ Test to Aid U.S. Clinicians in the Early Detection of Oral Cancer

Vigilant Biosciences Announces the Launch of the OncAlert Labs OraMark™ Test to Aid U.S. Clinicians in the Early Detection of Oral Cancer May 31, 2016 FORT LAUDERDALE, Florida and CHICAGO Vigilant Biosciences, Inc. (“Vigilant”), a leading innovator and developer of solutions that aid in the early detection and intervention of cancer, today announced the launch

Fort Lauderdale Biotech Company Launches Oral Cancer Test

Fort Lauderdale Biotech Company Launches Oral Cancer Test May 31, 2016 Vigilant Biosciences is making its oral rinse test available to dentists in the United States, the Fort Lauderdale startup company said Tuesday. The laboratory test is designed to measure a biomarker for oral cancer detection at its earliest stages. The OncAlert Labs OraMark Test

Vigilant Biosciences, Inc. Names Scientific Advisory Board and Expands Leadership Team, Appoints Dr. Michael Donovan as Chief Clinical Officer

Vigilant Biosciences, Inc. Names Scientific Advisory Board and Expands Leadership Team, Appoints Dr. Michael Donovan as Chief Clinical Officer May 25, 2016 FORT LAUDERDALE, Florida Vigilant Biosciences, Inc. (“Vigilant”), a leading innovator and developer of solutions that aid in the early detection and intervention of cancer, today announced the launch of a Scientific Advisory Board

Vigilant Creates New Clinical Officer Position

Vigilant Creates New Clinical Officer Position May 25, 2016 Vigilant Biosciences has appointed Michael Donovan, MD, PhD, as the its new chief clinical officer. Dr. Donovan will be part of the executive management team and is responsible for advancing Vigilant’s oral cancer product line. He received his medical degree from the University of Medicine and

Vigilant Biosciences’ Scientific Founder and Chief Scientific Officer, Elizabeth Franzmann, M.D., is Honored by Greater Miami Chamber of Commerce with 2016 Health Care Heroes® Award

Vigilant Biosciences’ Scientific Founder and Chief Scientific Officer, Elizabeth Franzmann, M.D., is Honored by Greater Miami Chamber of Commerce with 2016 Health Care Heroes® Award May 17, 2016 FORT LAUDERDALE, Florida Vigilant Biosciences, Inc. (“Vigilant”), a leading innovator and developer of solutions that aid in the early detection and intervention of cancer, announced today that

Vigilant Biosciences Receives CE Mark for OncAlert Oral Cancer Rapid Test

Vigilant Biosciences Receives CE Mark for OncAlert Oral Cancer Rapid Test May 13, 2016 The CE mark, a mandatory conformity marking in the European Union (EU), will allow the product to be sold in the 28 countries of the EU and Norway, Iceland, Liechtenstein and Switzerland. Vigilant Biosciences Inc. has announced that it has CE

Vigilant Biosciences Cleared to Launch its Oral Cancer Test Across Europe

Vigilant Biosciences Cleared to Launch its Oral Cancer Test Across Europe May 4, 2016 Vigilant Biosciences, an early-stage Fort Lauderdale-based company that develops solutions that aid in the early detection and intervention of cancer, announced that it has CE Marked its OncAlert Oral Cancer RAPID Test, meaning it can market the product in the 28

Fort Lauderdale Company’s CancerTest Receives European Marketing Approval

Fort Lauderdale Company’s CancerTest Receives European Marketing Approval May 4, 2016 Vigilant Biosciences, a startup company in Fort Lauderdale, has received European Commission approval to market its oral cancer testing product. European approval to sell the product “is a major milestone for our company as it enables us to initiate manufacturing and sales efforts across

Vigilant Biosciences Receives CE Mark for OncAlert® Oral Cancer RAPID Test to Aid in Diagnosis of Oral Cancer

Vigilant Biosciences Receives CE Mark for OncAlert® Oral Cancer RAPID Test to Aid in Diagnosis of Oral Cancer May 4, 2016 FORT LAUDERDALE, Florida Vigilant Biosciences, Inc. (“Vigilant”), a leading innovator and developer of solutions that aid in the early detection and intervention of cancer, today announced that it has CE Marked its OncAlert® Oral Cancer

© 2020 Vigilant Biosciences

Follow Us

3900001 Rev C